Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have made a discovery in the field of genetic regulation, highlighting the critical role of Alu elements in diseases such as tumor formation and neurodegenerative disorders.Alu elements, which make up about 10 percent of
Curacle announced top-line results from its U.S. phase 2a clinical trial of CU06, an oral treatment for diabetic macular edema, on Monday."In this short-term, three-month trial, we found that CU06 blocked endothelial dysfunction and improved visual acuity, with a 5.8 increase in the number of letter
Some users of spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) failed to get reimbursement because their motor function was not maintained or improved after its administration.The Health Insurance Review and Assessment Service (HIRA) released the results of the recent Medical Review and
Janssen's antidepressant Spravato (esketamine) has failed to demonstrate efficacy in clinical trials in China following Japan, raising questions about its effectiveness in Koreans.The Central Pharmaceutical Review Committee under the Ministry of Food and Drug Safety (MFDS) concluded that the drugmak
Celltrion said that Rani Therapeutics has reported positive topline results from its phase 1 clinical trial of RT-111, an oral form of ustekinumab.The trial, conducted in Australia, involved 55 healthy adults and aimed to evaluate the pharmacokinetics (PK) and safety of RT-111, showcasing an impress
Chong Kun Dang said its consolidated operating profit surged by 124.4 percent on-year to 246.6 billion won ($184.7 million) in 2023, marking a record achievement thanks to its recent licensing deal with Novartis.The company's annual revenue increased by 12.2 percent to 1.6 trillion won last year, se
Daewoong Pharmaceutical said that the company achieved its highest-ever annual performance in 2023 across three key metrics -- sales, operating profit, and operating profit margin.On a standalone basis, the company reported sales of 1.2 trillion won ($900 million), an operating profit of 133.4 billi
A Korean research team has presented a method to accurately predict lung cancer by analyzing the bronchi microbiome.Chungnam National University Hospital said Monday that a research team led by Professors Jeong Jae-wook and Kang Da-hyun of the Department of Respiratory and Allergy Medicine recently
As the government prepares to announce an increase in medical school enrollment quotas before the Lunar New Year holidays, the medical community is on edge.Following an emergency meeting by the Korean Intern and Resident Association (KIRA) last Friday, the Korean Medical Association (KMA) held a boa
Neurophet and ReadyCure said they have signed a business agreement to exchange business and conduct projects related to developing an Alzheimer's disease treatment.Under the accord, Neurophet will cooperate on developing ReadyCure's upcoming dementia treatment medical device, Helaxon.Utilizing its a
Waycen, a medical AI company, said Monday that it has been certified as the “No. 7 Innovative Medical Device Software Manufacturer” by the Ministry of Food and Drug Safety (MFDS).Waycen won the certification for its continuous quality management efforts, including product development, verification,
Ahn-gook Pharmaceutical has completed preparations to move to its new headquarters office in Gwacheon, south of Seoul, in April.Ahn-gook said Monday that it made the remaining payment of about 59.1 billion won ($44.3 million) for purchasing its Gwacheon headquarters through a correction announcement
Medipost has voluntarily withdrawn its phase 2 clinical trial of Cartistem in Japan. The company said it did so to focus on a separate phase 3 monotherapy study.In a public disclosure Friday, Medipost said it has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) f
More than seven months have passed since MSD Korea’s application for expanding coverage for 13 indications of Keytruda (pembrolizumab) was stuck in the Cancer Disease Review Committee (CDRC), prompting anxious patients to request the review of individual indications.Contrary to MSD Korea's intention
VUNO said it has achieved its highest annual revenue since its inception in 2014, thanks to a surge in revenue for VUNO Med-DeepCARS, its artificial intelligence (AI)-based cardiac arrest prediction solution, and increased sales in both domestic and international markets for its other AI medical ima
Government officials said they would authorize non-physicians, such as nurses and other professionals, to conduct cosmetic procedures like botulinum toxins (BTX) and fillers, citing the examples of North America and Europe.However, North Americans and Europeans inject BTX and fillers quite shallowly
In 2023, the life sciences sector, particularly Big Pharma, has witnessed a significant return to large-scale deal making.This resurgence is primarily driven by the looming patent cliff, with numerous key products facing the loss of patent protection within the next five years.The EY (Ernst & Young)
GI Cell, an affiliate of GI Innovation, has submitted an application to the Ministry of Food and Drug Safety for phase 1/2a clinical trials to evaluate the safety and efficacy of a combination therapy between GI Cell's allogeneic NK cell therapy, T.O.P. NK and GI-101A, in patients with recurrent and
Hanmi Pharm reported a groundbreaking performance for 2023, with consolidated sales and operating profit reaching 1.49 trillion won ($1.1 billion) and 220.7 billion won, up 11.97 percent and 39.5 percent from the previous year, thanks to royalties and strong domestic sales.The company also reported
LifeSemantics has completed a local proof of concept (PoC) for its new non-face-to-face healthcare platform, “Dr.Call Thai,” to enter the Thai market.The technology demonstration was conducted with Praram 9 Hospital, a tertiary general hospital in Bangkok, to review the service performance of Dr. Ca